SiRNA against plasminogen activator inhibitor-1 ameliorates bleomycin-induced lung fibrosis in rats

Acta Pharmacologica Sinica

Volumn 33, Issue 7, 2012, Pages 897-908

  Zhang, Yan Ping ^a   Li, Wen Bin ^a   Wang, Wei Li ^a   Liu, Jian ^a   Song, Shu Xia ^b   Bai, Lin Lin ^a   Hu, Yu Yan ^a   Yuan, Ya Dong ^a   Zhang, Min ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Aging and Cognition Neuroscience Laboratory of Hebei Province   (China)

Author keywords

a smooth muscle actin; bleomycin; caspase 3; collagen; extracellular signal regulated kinase; idiopathic pulmonary fibrosis; phosphatidylinositol 3 phosphate kinase; plasminogen activator inhibitor 1; pulmonary fibroblast; RNA interference

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BLEOMYCIN; CASPASE 3; COLLAGEN TYPE 1; COLLAGEN TYPE 3; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLASMID DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 SMALL INTERFERING RNA; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; FIBROBLAST; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LUNG FIBROSIS; MALE; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACTINS; ANIMALS; APOPTOSIS; BLEOMYCIN; CASPASE 3; CELLS, CULTURED; COLLAGEN; FIBROBLASTS; HYDROXYPROLINE; LUNG; MALE; MAP KINASE SIGNALING SYSTEM; PHOSPHATIDYLINOSITOL 3-KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULMONARY FIBROSIS; RATS; RATS, WISTAR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84863698127     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.39     Document Type: Article

References (34)

1. Doubková M, Skhicková J. Idiopathic pulmonary fibrosis. Vnitr Lek 2005; 51: 1375-84.
2. Hinz B, Phan SH, Thannickal VJ, Galli A, Bochaton-Piallat ML, Gabbiani G. The myofibroblast: one function, multiple origins. Am J Pathol 2007; 170: 1807-16.
3. Hildenbrand R, Gandhari M, Stroebel P, Marx A, Allgayer H, Arens N. The urokinase-system-role of cell proliferation and apoptosis. Histol Histopathol 2008; 23: 227-36.
4. Bueno M, Salgado S, Beas-Zárate C, Armendariz-Borunda J. Urokinase-type plasminogen activator gene therapy in liver cirrhosis is mediated by collagens gene expression down-regulation and upregulation of MMPs, HGF and VEGF. J Gene Med 2006; 8: 1291-9.
5. Hattori N, Mizuno S, Yoshida Y, Chin K, Mishima M, Sisson TH, et al. The plasminogen activation system reduces fibrosis in the lung by a hepatocyte growth factor-dependent mechanism. Am J Pathol 2004; 164: 1091-8.
6. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322: 890-7.
7. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-7.
8. Chuang-Tsai S, Sisson TH, Hattori N, Tsai CG, Subbotina NM, Hanson KE, et al. Reduction in fibrotic tissue formation in mice genetically deficient in plasminogen activator inhibitor-1. Am J Pathol 2003; 163: 445-52.
9. Hu PF, Zhu YW, Zhong W, Chen YX, Lin Y, Zhang X, et al. Inhibition of plasminogen activator inhibitor-1 expression by siRNA in rat hepatic stellate cells. J Gastroenterol Hepatol 2008; 23: 1917-25.
10. Senoo T, Hattori N, Tanimoto T, Furonaka M, Ishikawa N, Fujitaka K, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010; 65: 334-40.
11. Durcan N, Murphy C, Cryan SA. Inhalable siRNA: potential as a therapeutic agent in the lungs. Mol Pharm 2008; 5: 559-66.
12. Castanotto D, Rossi1 JJ. The promises and pitfalls of RNAinterference-based therapeutics. Nature 2009; 457: 426-33.
13. Thannickal VJ, Horowitz JC. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3: 350-6.
14. Hinz B, Gabbiani G. Cell-matrix and cell-cell contacts of myofibroblasts: role in connective tissue remodeling. Thromb Haemost 2003; 90: 993-1002.
15. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 2002; 122: 286S-9S.
16. Offersen BV, Nielsen BS, Høyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003; 163: 1887-99.
17. Bernstein AM, Twining SS, Warejcka DJ, Tall E, Masur SK. Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation. Mol Bio Cell 2007; 18: 2716-27.
18. Hu PF, Chen H, Zhong W, Lin Y, Zhang X, Chen YX, et al. Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats. J Hepatol 2009; 51: 102-13.
19. Dellas C, Loskutoff DJ. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 2005; 93: 631-40.
20. Binder BR, Mihaly J, Prager GW. UPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost 2007; 97: 336-42.
21. Balsara RD, Ploplis VA. Plasminogen activator inhibitor-1: the doubleedged sword in apoptosis. Thromb Haemost 2008; 100: 1029-36.
22. Lademann UA, Rømer MU. Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thromb Haemost 2008; 100: 1041-6.
23. Al-Fakhri N, Chavakis T, Schmidt-Wöll T, Huang B, Cherian SM, Bobryshev YV, et al. Induction of apoptosis in vascular cells by plasminogen activator inhibitor-1 and high molecular weight kininogen correlates with their anti-adhesive properties. Biol Chem 2003; 384: 423-35.
24. Chen SC, Henry DO, Reczek PR, Wong MK. Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis. Mol Cancer Ther 2008; 7: 1227-36.
25. Rømer MU, Larsen L, Offenberg H, Brünner N, Lademann UA. Plasminogen activator inhibitor 1 protects fibrosarcoma cells from etoposide-induced apoptosis through activation of the PI3K/Akt cell survival pathway. Neoplasia 2008; 10: 1083-91.
26. Chen Y, Budd RC, Kelm RJ Jr, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol 2006; 26: 1777-83.
27. Bauman KA, Wettlaufer SH, Okunishi K, Vannella KM, Stoolman JS, Huang SK, et al. The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Invest 2010; 120: 1950-60.
28. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, et al. Structure of human urokinase plasminogen activator in complex with its receptor. Science 2006; 311: 656-9.
29. Horowitz JC, Rogers DS, Simon RH, Sisson TH, Thannickal VJ. Plasminogen activation induced pericellular fibronectin proteolysis promotes fibroblast apoptosis. Am J Respir Cell Mol Biol 2008; 38: 78-87.
30. Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERK (MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38 (SAPK). Cancer Res 2003; 63: 1684-95.
31. Ma Z, Thomas KS, Webb DJ, Moravec R, Salicioni AM, Mars WM, et al. Regulation of Rac1 activation by the low density lipoprotein receptorrelated protein. J Cell Biol 2002; 159: 1061-70.
32. Kiian I, Tkachuk N, Haller H, Dumler I. Urokinase-induced migration of human vascular smooth muscle cells requires coupling of the small GTPases RhoA and Rac1 to the Tyk2/PI3-K signalling pathway. Thromb Haemost 2003; 89: 904-14.
33. Balsara RD, Castellino FJ, Ploplis VA. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006; 281: 22527-36.
34. Zhong W, Shen WF, Ning BF, Hu PF, Lin Y, Yue HY, et al. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology 2009; 50: 1524-36.